| Anesthesia and Neurotoxicity Research | Lifetime | 542 | CN 27 | 96.84 |
| Cardiac Ischemia and Reperfusion | Lifetime | 583 | CN 34 | 96.62 |
| Sirtuins and Resveratrol in Medicine | Lifetime | 635 | CN 110 | 90.11 |
| Cervical and Thoracic Myelopathy | Lifetime | 840 | CN 73 | 91.89 |
| Magnolia and Illicium research | Lifetime | 793 | CN 308 | 43.42 |
| Cardiac Ischemia and Reperfusion | 2021-2025 | 3 | CN 1 | 98.08 |
| Autophagy in Disease and Therapy | 2021-2025 | 46 | CN 20 | 97.51 |
| Adipose Tissue and Metabolism | 2021-2025 | 86 | CN 18 | 96.93 |
| Inflammasome and immune disorders | 2021-2025 | 55 | CN 24 | 97.18 |
| Nutrition and Health in Aging | 2021-2025 | 172 | CN 21 | 97.64 |
| Metabolomics and Mass Spectrometry Studies | 2021-2025 | 148 | CN 43 | 95.47 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 906 | CN 140 | 96.17 |
| Mitochondrial Function and Pathology | 2021-2025 | 287 | CN 35 | 93.42 |
| MicroRNA in disease regulation | 2021-2025 | 559 | CN 341 | 94.16 |
| Endoplasmic Reticulum Stress and Disease | 2021-2025 | 126 | CN 24 | 90.91 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 774 | CN 31 | 95.05 |
| Diet, Metabolism, and Disease | 2021-2025 | 247 | CN 31 | 93.13 |
| Frailty in Older Adults | 2021-2025 | 427 | CN 44 | 93.12 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 110 | CN 33 | 88.41 |
| Extracellular vesicles in disease | 2021-2025 | 958 | CN 558 | 89.59 |
| Musculoskeletal synovial abnormalities and treatments | 2021-2025 | 103 | CN 5 | 88.01 |
| Central Venous Catheters and Hemodialysis | 2021-2025 | 324 | CN 9 | 88.03 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 957 | CN 430 | 86.26 |
| Body Composition Measurement Techniques | 2021-2025 | 390 | CN 35 | 84.84 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 566 | CN 106 | 82.30 |
| Anesthesia and Neurotoxicity Research | 2021-2025 | 433 | CN 137 | 82.26 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 786 | CN 474 | 80.92 |
| Shoulder and Clavicle Injuries | 2021-2025 | 689 | CN 21 | 84.47 |
| Heme Oxygenase-1 and Carbon Monoxide | 2021-2025 | 416 | CN 181 | 73.42 |
| Infectious Diseases and Tuberculosis | 2021-2025 | 808 | CN 98 | 72.46 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 478 | CN 156 | 67.17 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 818 | CN 404 | 66.18 |
| Adenosine and Purinergic Signaling | 2021-2025 | 749 | CN 176 | 66.28 |
| Vascular anomalies and interventions | 2021-2025 | 612 | CN 68 | 59.47 |
| Infectious Aortic and Vascular Conditions | 2021-2025 | 699 | CN 100 | 57.86 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 732 | CN 151 | 59.56 |
| Hemoglobin structure and function | 2021-2025 | 712 | CN 99 | 36.80 |
